Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, usually with an
indolent course. ALK fusions are rare in PTC but may give rise to a more aggressive …

Little is known about the efficacy of alectinib for papillary thyroid cancer with STRN-ALK
fusion. A 64-year-old female presented with metastatic papillary thyroid cancer, widespread …

Medullary thyroid carcinoma (MTC) is most commonly associated with RET gene mutations.
ALK fusions have rarely been described, although not previously in pediatrics and not …

Anaplastic lymphoma kinase (ALK) gene fusions are rare in papillary thyroid carcinoma
(PTC) but may serve as a therapeutic target. This study aims to evaluate the preoperative …

Thyroid carcinoma is the most common endocrine malignant tumor and accounts for 1% of
all new malignant diseases. Among all types and subtypes of thyroid cancers that have been …

ALK fusions are found in various tumors, including thyroid cancer, and serve as a diagnostic
marker and therapeutic target. Spectrum and outcomes of ALK fusions found in thyroid …

Anaplasic thyroid cancer (ATC) represents* 2% of all thyroid carcinomas, and is one of the
most aggressive human malignancies. The mainstay of treatment in the advanced setting is …

Discussion Various ALK rearrangements have been previously described, with the EML4-
ALK fusion variants being the most common. 1 STRN is located in the very same short arm …

BACKGROUND Oncocytic carcinoma of the thyroid is a rare disease, characterized by a
poor prognosis and low response rate to radioiodine therapy. Crizotinib is a specific …

Finding targetable gene fusions can expand the limited treatment options in radioactive
iodine-refractory (RAI-r) thyroid cancer. To that end, we established a novel cell line …